Your browser doesn't support javascript.
loading
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations.
Slusarczyk, Aleksander; Baboudjian, Michael; Zapala, Piotr; Yanagisawa, Takafumi; Miszczyk, Marcin; Chlosta, Marcin; Krumpoeck, Paul; Moschini, Marco; Gandaglia, Giorgio; Ploussard, Guillaume; Rivas, Juan G; Zyczkowski, Marcin; Karakiewicz, Pierre I; Radziszewski, Piotr; Leapman, Michael S; Shariat, Shahrokh F; Rajwa, Pawel.
Afiliación
  • Slusarczyk A; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
  • Baboudjian M; Department of Urology, APHM, North Academic Hospital, Marseille, France.
  • Zapala P; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
  • Yanagisawa T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Miszczyk M; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Chlosta M; IIIrd Radiotherapy and Chemotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland.
  • Krumpoeck P; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Moschini M; Department of Urology, Jagiellonian University in Cracow, Kraków, Poland.
  • Gandaglia G; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Ploussard G; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Rivas JG; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Zyczkowski M; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
  • Karakiewicz PI; Department of Urology, Clinico San Carlos Hospital, Madrid, Spain.
  • Radziszewski P; Department of Urology, Medical University of Silesia, Zabrze, Poland.
  • Leapman MS; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
  • Shariat SF; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
  • Rajwa P; Department of Urology, Yale School of Medicine, New Haven, Connecticut, USA.
Prostate ; 83(15): 1504-1515, 2023 11.
Article en En | MEDLINE | ID: mdl-37545342
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Prostate Año: 2023 Tipo del documento: Article País de afiliación: Polonia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Prostate Año: 2023 Tipo del documento: Article País de afiliación: Polonia